UNSPSC 51162709: Cistinexine

This classification denotes a mucolytic agent and expectorant with the molecular formula C50H60Br4N6O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 62VR67FK8E, chemically known as 2-oxa-7,8-dithia-4,11-diazadodecan-12-oic acid, 5,10-bis(((2,4-dibromo-6-((cyclohexylmethylamino)methyl)phenyl)amino)carbonyl)-3-oxo-1-phenyl-, phenylmethyl ester, (r-(r*,r*))- but more generally known as cistinexine, which bears US NIH Compound Identifier 65644.

UNSPSC 51162709 Cistinexine, a Commodity code, encompasses pharmaceutical products and related services that state and local governments procure for healthcare delivery to incarcerated and community populations. Based on recent solicitations, the code captures parenteral nutrition solutions, intravenous products, and other injectable pharmaceuticals requiring specialized preparation, handling, and delivery protocols. State and local issuing bodies under this code include departments of corrections and county health agencies. The Washington State Department of Corrections and Seminole County, Florida represent the recent buyer base, with work spanning facility-based healthcare provision and community health initiatives. Scope includes not only product supply but also preparation services, delivery logistics with tight timing windows, patient monitoring coordination, and formula adjustment capabilities for medically individualized care.

Activity under the code appears concentrated in Washington and Florida based on recent postings. The Washington State Department of Corrections issued RFQ RFQQK13020 on September 8, 2026 seeking parenteral products, services, and equipment for eight correctional facilities across three regions, with responses due October 7, 2026 and pre-bid conference on September 23, 2026; the contract anticipates multiple awards (up to three per region) with a term running November 26, 2026 through June 30, 2030 and pricing fixed for the initial two-year period. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building. Both solicitations emphasize compliance with state business licensing, insurance coverage including professional and cyber liability, and drug-free workplace requirements; the Washington solicitation explicitly encourages small-business, minority-owned, women-owned, and veteran-owned enterprise participation with documented state certifications.